evipedia.ai
← Back

Methylene Blue for Health & Longevity

Created on 11/05/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Methylene blue, an old dye turned medicine, is taken for brain health and healthy aging. Its strongest evidence lies outside longevity: malaria, intensive-care low blood pressure, confusion after surgery. Small trials eased bipolar depression; daily-use memory gains are unconfirmed; aging claims rest on cell and animal work. It can interact dangerously with common antidepressants, destroy red blood cells in an inherited enzyme deficiency and may harm a developing baby. (Full Review)

Protocol

Daily cognition approach
282 mg/day
For 12 weeks in healthy aging and mild cognitive impairment; no longevity regimen tested
Daily mood approach
195 or 300 mg/day
Added to lamotrigine or lithium, respectively, in bipolar disorder
Time of day
Morning or early-day with food
Common practice; food reduced vomiting; no study has examined sleep effects
Time to effect
Mood in bipolar disorder
Within 3 months
Emerged within the trial treatment periods
Brain activity and memory
1 hour
Measured after a single dose

Benefits

Contraindications
  • G6PD deficiency
  • Prior severe hypersensitivity to methylene blue or other thiazine dyes
  • People taking serotonergic drugs or opioids
  • Pregnancy
  • Breastfeeding (during and for up to 8 days after treatment)
  • Moderate or severe kidney impairment (eGFR 15–59 mL/min/1.73 m²)
  • Liver impairment
    •
Key Interactions
  • SSRIs and SNRIs (sertraline, fluoxetine, venlafaxine): Avoid; no serotonergic drug within 72 hours after the last dose
  • Other serotonergic drugs (MAO inhibitors such as phenelzine and tranylcypromine, clomipramine, bupropion, linezolid): Avoid; same 72-hour separation
  • Opioids (tramadol, meperidine, fentanyl): Avoid
  • Dextromethorphan: Avoid
  • Chloroquine: Higher methylene blue plasma levels, judged not clinically relevant
  • Artesunate: Higher exposure to its active metabolite dihydroartemisinin
  • Triptans (sumatriptan): Avoid; same 72-hour separation
    •
Theoretical (inferred from mechanism)
  • Serotonergic supplements (St John's wort, 5-HTP, L-tryptophan): Could precipitate serotonin syndrome
  • Tyramine-rich foods (aged cheese, cured meats): Could raise blood pressure
  • Oxidant drugs (dapsone, primaquine, nitrofurantoin): Could cause hemolysis, especially with G6PD deficiency
  • Nitrates and PDE5 inhibitors (nitroglycerin, sildenafil): Could blunt their vessel-relaxing effect
  • UGT1A4 or P-gp substrates (lamotrigine, digoxin): Could raise their blood levels
  • Photosensitizing drugs and light therapy (doxycycline, red or near-infrared light): Could cause skin reactions
    •

Risk & Side Effects

  • High: Blue-green discoloration of urine and skin; blood pressure elevation
    •
  • Medium: Serotonin syndrome with serotonergic drugs; hemolytic anemia, especially in G6PD deficiency; gastrointestinal and urinary irritation; postoperative fever after intravenous use
    •
  • Low: Hypersensitivity and anaphylaxis; fetal harm in pregnancy; high-dose toxicity; headache, myoclonus, seizure-like events and low electrolytes; falsely low pulse-oximetry readings; phototoxicity; skin necrosis at injection sites
    •
  • Speculative: Genotoxicity and rodent carcinogenicity; impaired cognition at higher doses
    •

Monitoring

Marker Target Why
G6PD activity 7.0–20.5 U/g hemoglobin Deficiency stops use
Hemoglobin Men 13.5–17.5 g/dL; women 12.0–15.5 g/dL A fall signals hemolysis
Indirect bilirubin 0.2–0.8 mg/dL A rise signals hemolysis
Haptoglobin 30–200 mg/dL A fall signals hemolysis
eGFR ≥60 mL/min/1.73 m² Low values limit dosing
ALT 7–56 U/L Liver injury changes use
AST Not specified in the ER Pairs with ALT
Methemoglobin 0–1.5% of total hemoglobin High-dose toxicity
Blood pressure No established target; track change from own baseline A rise changes use

Cadence: Baseline G6PD, complete blood count, kidney and liver function and blood pressure; hemoglobin and hemolysis markers at 1–2 weeks, then every 3 months during daily use; kidney and liver tests every 6–12 months; home blood pressure during the first week and after dose increases

Qualitative Assessment

  • Mood: A validated questionnaire such as the Patient Health Questionnaire-9, compared with baseline
  • Memory and attention: A repeatable cognitive test or a structured self-rating, compared with baseline
  • Energy and fatigue: Daily self-rating during the first month
  • Sleep quality: Sleep onset, awakenings and morning alertness
  • Side effects: Expected blue urine; digestive upset, headache, dizziness, skin reactions; agitation, tremor or fever as stop signals
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.